Gamida Cell Temettü

Temettü kriter kontrolleri 0/6

Gamida Cell şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-2,359.6%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-2,359.6%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Gamida stock rises 13% as FDA grants priority review to stem cell therapy omidubicel

Aug 01

Does Gamida Cell (NASDAQ:GMDA) Have A Healthy Balance Sheet?

Feb 23

Gamida Cell: Recapping A Tough Year

Nov 02

Gamida Cell (NASDAQ:GMDA) Has Debt But No Earnings; Should You Worry?

Nov 02

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: GMDA.Q şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: GMDA.Q şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Gamida Cell Piyasaya Karşı Temettü Getirisi

GMDA.Q temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (GMDA.Q)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.6%
Sektör Ortalaması (Biotechs)	2.2%
Analist tahmini (GMDA.Q) (3 yıla kadar)	n/a

Önemli Temettü: GMDA.Q şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, GMDA.Q şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: GMDA.Q şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: GMDA.Q herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Gamida Cell Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC

Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer

Gamida Cell Files Form 15

Gamida Cell Ltd. announced delayed 10-Q filing

New major risk - Negative shareholders equity

Gamida Cell Ltd. announced that it expects to receive $30 million in funding from Highbridge Capital Management, LLC

Gamida Cell Ltd. to Report Q4, 2023 Results on Mar 27, 2024

Gamida Cell Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of Nasdaq Listing Rule 5450(a)(1)

Gamida Cell Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of Nasdaq Listing Rule 5450(a)(1)

Gamida Cell Ltd. Announces Resignation of Mr. Jeremy Blank as Board of Director

Price target decreased by 43% to US$4.00

Gamida Cell Ltd. has filed a Follow-on Equity Offering in the amount of $50 million.

Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer Annual Meeting

Gamida Cell Ltd. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Market cap size

Gamida Cell Ltd. Reports Preliminary Data from Phase 1 Study of Natural Killer Cell Therapy Candidate GDA-201

New minor risk - Share price stability

Gamida Cell Ltd. Announces First Patient Receives Omisirge (Omidubicel-Onlv)

Gamida Cell Ltd., Annual General Meeting, Oct 19, 2023

Consensus EPS estimates fall by 12%

Gamida Cell Ltd. to Report Q2, 2023 Results on Aug 14, 2023

Gamida Cell Ltd. Announces Publication in Prospective Sub- Study of the Phase 3 Clinical Trial for Omisirge®

Forecast to breakeven in 2025

Gamida Cell Ltd. Appoints Terry Coelho as its Principal Financial Officer and Principal Accounting Officer

Price target decreased by 11% to US$6.80

Gamida Cell Ltd. to Report Q1, 2023 Results on May 15, 2023

Forecast to breakeven in 2025

Consensus revenue estimates increase by 70%

Forecast to breakeven in 2025

Price target decreased by 48% to US$6.40

Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR

Gamida Cell Ltd. announced that it has received $25 million in funding from Highbridge Capital Management, LLC

Gamida Cell Ltd. Provides Regulatory Update on Omidubicel

Price target decreased to US$12.60

Gamida Cell Ltd. Announces Encouraging Preclinical Data on GDA-501

Independent Chairman of the Board recently bought US$78k worth of stock

Gamida Cell Ltd. announced that it expects to receive $25 million in funding from Highbridge Capital Management, LLC

Gamida Cell shares slide after stock offering

Gamida Cell Ltd. Announces Executive Changes

Gamida appoints Emergent’s former head of vaccines as new CEO

Gamida Cell Q2 2022 Earnings Preview

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

Gamida stock rises 13% as FDA grants priority review to stem cell therapy omidubicel

Gamida Cell Ltd., Annual General Meeting, Jul 27, 2022

No longer forecast to breakeven

Gamida Cell Ltd. Announces Board Changes

Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel

Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022

Gamida Cell Ltd. Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel At 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Price target decreased to US$15.00

Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201

Gamida Cell Ltd. Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Consensus forecasts updated

Does Gamida Cell (NASDAQ:GMDA) Have A Healthy Balance Sheet?

Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel

Forecast to breakeven in 2024

Gamida Cell Ltd. Announces Board Appointments

Gamida Cell Provides Update on Omidubicel BLA Submission

Gamida Cell Presents New Omidubicel Data at 63rd ASH Annual Meeting

Independent Director David Fox has left the company

Price target decreased to US$14.57

Price target decreased to US$17.86

Gamida Cell: Recapping A Tough Year

Gamida Cell (NASDAQ:GMDA) Has Debt But No Earnings; Should You Worry?

Independent Director Nurit Benjamini has left the company

Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Require an Allogeneic Stem Cell Transplant

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin